Latest Pharma Insights
Ascentage Sees Benefit To Launching In China First
CEO Dajun Yang explained in an interview at ASCO that experience with commercialization in China is an advantage as the firm enters global markets.
Scrip - June 18, 2026
CEO Dajun Yang explained in an interview at ASCO that experience with commercialization in China is an advantage as the firm enters global markets.
Scrip - June 18, 2026
Finance Watch: Kos Launches With A $123m Global Life Science VC Fund
Private Company Edition: Kos Biotechnology Partners’ $123m venture capital fund is the largest-ever life science VC fund based in Greece. Also, Beren raised $165m initially through new financings totaling up to $300m to fund its Niemann-Pick drug launch.
Scrip - June 18, 2026
Private Company Edition: Kos Biotechnology Partners’ $123m venture capital fund is the largest-ever life science VC fund based in Greece. Also, Beren raised $165m initially through new financings totaling up to $300m to fund its Niemann-Pick drug launch.
Scrip - June 18, 2026
EU Omnibus VI Provisional Agreement Advances CMR Phase-Out For Beauty
The provisional Omnibus VI agreement would introduce new transition periods for cosmetics containing newly classified CMR substances; the agreement is lauded by cosmetics and fragrance industry groups.
HBW Insight - June 18, 2026
The provisional Omnibus VI agreement would introduce new transition periods for cosmetics containing newly classified CMR substances; the agreement is lauded by cosmetics and fragrance industry groups.
HBW Insight - June 18, 2026
READI-Home FAQ: Modified Devices, Software And Pediatric Products All In Scope, FDA Confirms
A new FAQ for the FDA's READI-Home Innovation Challenge confirms that modified devices, software regulated as devices, and pediatric products may all be eligible for the program, which is designed to accelerate authorization of home-use devices that can help reduce hospital readmissions.
Medtech Insight - June 18, 2026
A new FAQ for the FDA's READI-Home Innovation Challenge confirms that modified devices, software regulated as devices, and pediatric products may all be eligible for the program, which is designed to accelerate authorization of home-use devices that can help reduce hospital readmissions.
Medtech Insight - June 18, 2026
Asia Deal Watch: LG Chem Calls On LabGenius’s AI Capabilities For Multispecific Antibodies
Plus deals involving JCR/Acumen, Everest/Dimerix, Dr. Reddy’s/Innoviva, Harbour Biomed/BioMap, Laekna/Vasque, WestGene/Cartesian and more.
Scrip - June 18, 2026
Plus deals involving JCR/Acumen, Everest/Dimerix, Dr. Reddy’s/Innoviva, Harbour Biomed/BioMap, Laekna/Vasque, WestGene/Cartesian and more.
Scrip - June 18, 2026
Solius Labs’ Wall-Mountable Light Launches As First FDA-Cleared OTC UVB Therapy Device
New FDA product code and $2,995 price, with no insurance required, position Solius Labs' personalized UVB panel as a scalable alternative to clinic-based phototherapy.
HBW Insight - June 18, 2026
New FDA product code and $2,995 price, with no insurance required, position Solius Labs' personalized UVB panel as a scalable alternative to clinic-based phototherapy.
HBW Insight - June 18, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news: FTC prioritizes false claims for children’s products; FDA maintains industry’s GMP annual burden; kidney injury warning added to alli label; more formula safety troubles; Texas investigates protein; Ohio hemp reg delayed.
HBW Insight - June 18, 2026
Weekly digest of US consumer health industry, marketplace news: FTC prioritizes false claims for children’s products; FDA maintains industry’s GMP annual burden; kidney injury warning added to alli label; more formula safety troubles; Texas investigates protein; Ohio hemp reg delayed.
HBW Insight - June 18, 2026
Integrum Creates AI Bionics Unit Afyri As Ukraine Reimbursement Decision Looms
Swedish bone-anchored prosthetics firm Integrum created subsidiary Afyri, led by Integrum founder Rickard Brånemark, to drive a next-gen intelligent bionics platform. Integrum awaits a reimbursement decision for its OPRA implant in Ukraine, where it has been used in over 100 surgeries since 2023.
Medtech Insight - June 18, 2026
Swedish bone-anchored prosthetics firm Integrum created subsidiary Afyri, led by Integrum founder Rickard Brånemark, to drive a next-gen intelligent bionics platform. Integrum awaits a reimbursement decision for its OPRA implant in Ukraine, where it has been used in over 100 surgeries since 2023.
Medtech Insight - June 18, 2026
PwC Finds Once-Quiet Medtech Deal Market Getting Louder In 2026
A PwC outlook finds record deal value masked by historically thin transaction volumes — and flags portfolio reshaping, private equity and AI as the forces most likely to define 2026.
Medtech Insight - June 18, 2026
A PwC outlook finds record deal value masked by historically thin transaction volumes — and flags portfolio reshaping, private equity and AI as the forces most likely to define 2026.
Medtech Insight - June 18, 2026
cAMPfield Launches With Phase II Plans For Prifemilast In IBD
The Mountainfield Venture Partners-backed start-up raised a $180m series A funding round to develop the PDE4 inhibitor in ulcerative colitis and Crohn’s disease.
Scrip - June 18, 2026
The Mountainfield Venture Partners-backed start-up raised a $180m series A funding round to develop the PDE4 inhibitor in ulcerative colitis and Crohn’s disease.
Scrip - June 18, 2026
Execs On The Move: June 8–12, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 18, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 18, 2026
Executives On The Move: Three CEOs, Four CMOs And Five CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at AdvanCell, MitoRx Therapeutics and Ambros Therapeutics, internal moves at Bayer, plus Soley Therapeutics gets a new CBO from Eli Lilly.
Scrip - June 18, 2026
Recent moves in the industry include C-suite changes at AdvanCell, MitoRx Therapeutics and Ambros Therapeutics, internal moves at Bayer, plus Soley Therapeutics gets a new CBO from Eli Lilly.
Scrip - June 18, 2026
Oryzon On The Up As AML Drug Nears Phase III
The Spanish biotech’s LSD1 inhibitors are advancing in both oncology and CNS.
Scrip - June 18, 2026
The Spanish biotech’s LSD1 inhibitors are advancing in both oncology and CNS.
Scrip - June 18, 2026
F2G, Shionogi Report Positive Phase III Results For Antifungal Olorofim In Invasive Aspergillosis
The companies have delivered positive late-stage data for investigational antifungal olorofim, marking a key development in the program's trajectory.
Scrip - June 18, 2026
The companies have delivered positive late-stage data for investigational antifungal olorofim, marking a key development in the program's trajectory.
Scrip - June 18, 2026
Clue-SDK Deal Opens A Parallel Route For Femtech Into Insured Care, Bypassing Germany’s DiGA
German private insurer SDK is funding access to Clue's period-tracking app for its members, a move Clue calls a world first. The deal sidesteps Germany's DiGA reimbursement framework, hinting at a parallel route for femtech into insured benefits.
Medtech Insight - June 18, 2026
German private insurer SDK is funding access to Clue's period-tracking app for its members, a move Clue calls a world first. The deal sidesteps Germany's DiGA reimbursement framework, hinting at a parallel route for femtech into insured benefits.
Medtech Insight - June 18, 2026
The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin
Generics Bulletin senior reporter Urt? Fultinavi?i?t? talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
Generics Bulletin - June 18, 2026
Generics Bulletin senior reporter Urt? Fultinavi?i?t? talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
Generics Bulletin - June 18, 2026
Dr Reddy’s Challenges Bosulif With 180-Day Lead
Through a partnership with MSN Laboratories, Dr Reddy’s has launched the first US generic version of Bosulif (bosutinib) 400mg tablets with 180-day exclusivity.
Generics Bulletin - June 18, 2026
Through a partnership with MSN Laboratories, Dr Reddy’s has launched the first US generic version of Bosulif (bosutinib) 400mg tablets with 180-day exclusivity.
Generics Bulletin - June 18, 2026
Sumatriptan Surge Drives UK Price Rises In May
Generic sumatriptan 50mg and 100mg tablets saw their average UK trade prices increase by more than five times in May, leading a raft of triple-digit rises that also included multiple presentations of digoxin.
Generics Bulletin - June 18, 2026
Generic sumatriptan 50mg and 100mg tablets saw their average UK trade prices increase by more than five times in May, leading a raft of triple-digit rises that also included multiple presentations of digoxin.
Generics Bulletin - June 18, 2026
FDA Review Revives Outlook’s Long-Delayed Bevacizumab Hopes
Outlook Therapeutics is nearing a pivotal FDA decision on Lytenava, raising hopes that the US could soon get its first approved ophthalmic bevacizumab for wet AMD after years of regulatory setbacks.
Generics Bulletin - June 18, 2026
Outlook Therapeutics is nearing a pivotal FDA decision on Lytenava, raising hopes that the US could soon get its first approved ophthalmic bevacizumab for wet AMD after years of regulatory setbacks.
Generics Bulletin - June 18, 2026
Italian Strikes Cloud Teva’s TAPI Divestment Plans
Teva’s TAPI restructuring is drawing labor opposition in Italy as its Villanterio site faces potential closure, while around 250 roles are set to go in Israel, as the API unit remains marked for eventual divestment.
Generics Bulletin - June 18, 2026
Teva’s TAPI restructuring is drawing labor opposition in Italy as its Villanterio site faces potential closure, while around 250 roles are set to go in Israel, as the API unit remains marked for eventual divestment.
Generics Bulletin - June 18, 2026
Biogen Buys RayThera, The Third Exit For Its Serial Founders
The founders of RayThera complete a hat-trick as Biogen snaps up the immunology-focused biotech for up to $1bn.
Scrip - June 18, 2026
The founders of RayThera complete a hat-trick as Biogen snaps up the immunology-focused biotech for up to $1bn.
Scrip - June 18, 2026
‘No Compromise’: How Opella Is Tackling The Hardest Parts Of Sustainability
Opella's chief manufacturing and supply officer, Rafik Amrane, talks to HBW Insight about the company's commitment to sustainability, emphasizing "there’s absolutely no compromise on what we do.”
HBW Insight - June 18, 2026
Opella's chief manufacturing and supply officer, Rafik Amrane, talks to HBW Insight about the company's commitment to sustainability, emphasizing "there’s absolutely no compromise on what we do.”
HBW Insight - June 18, 2026
GLP-1s, Insulins Reshaping China’s Drug Exports, Thanks To MNCs
As multinationals switched to partly supplying global markets from manufacturing facilities in China, the country’s exports of GLP-1 and insulin analog preparations surged in 2025 and well into 2026.
Scrip - June 18, 2026
As multinationals switched to partly supplying global markets from manufacturing facilities in China, the country’s exports of GLP-1 and insulin analog preparations surged in 2025 and well into 2026.
Scrip - June 18, 2026
Deals In Depth: May 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026
US Supplement Industry Questions Sources For Texas AG’s ‘Harmful Ingredients’ Investigation
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
Ascentage Sees Benefit To Launching In China First
CEO Dajun Yang explained in an interview at ASCO that experience with commercialization in China is an advantage as the firm enters global markets.
Scrip - June 18, 2026
CEO Dajun Yang explained in an interview at ASCO that experience with commercialization in China is an advantage as the firm enters global markets.
Scrip - June 18, 2026
Finance Watch: Kos Launches With A $123m Global Life Science VC Fund
Private Company Edition: Kos Biotechnology Partners’ $123m venture capital fund is the largest-ever life science VC fund based in Greece. Also, Beren raised $165m initially through new financings totaling up to $300m to fund its Niemann-Pick drug launch.
Scrip - June 18, 2026
Private Company Edition: Kos Biotechnology Partners’ $123m venture capital fund is the largest-ever life science VC fund based in Greece. Also, Beren raised $165m initially through new financings totaling up to $300m to fund its Niemann-Pick drug launch.
Scrip - June 18, 2026
Asia Deal Watch: LG Chem Calls On LabGenius’s AI Capabilities For Multispecific Antibodies
Plus deals involving JCR/Acumen, Everest/Dimerix, Dr. Reddy’s/Innoviva, Harbour Biomed/BioMap, Laekna/Vasque, WestGene/Cartesian and more.
Scrip - June 18, 2026
Plus deals involving JCR/Acumen, Everest/Dimerix, Dr. Reddy’s/Innoviva, Harbour Biomed/BioMap, Laekna/Vasque, WestGene/Cartesian and more.
Scrip - June 18, 2026
cAMPfield Launches With Phase II Plans For Prifemilast In IBD
The Mountainfield Venture Partners-backed start-up raised a $180m series A funding round to develop the PDE4 inhibitor in ulcerative colitis and Crohn’s disease.
Scrip - June 18, 2026
The Mountainfield Venture Partners-backed start-up raised a $180m series A funding round to develop the PDE4 inhibitor in ulcerative colitis and Crohn’s disease.
Scrip - June 18, 2026
Executives On The Move: Three CEOs, Four CMOs And Five CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at AdvanCell, MitoRx Therapeutics and Ambros Therapeutics, internal moves at Bayer, plus Soley Therapeutics gets a new CBO from Eli Lilly.
Scrip - June 18, 2026
Recent moves in the industry include C-suite changes at AdvanCell, MitoRx Therapeutics and Ambros Therapeutics, internal moves at Bayer, plus Soley Therapeutics gets a new CBO from Eli Lilly.
Scrip - June 18, 2026
Oryzon On The Up As AML Drug Nears Phase III
The Spanish biotech’s LSD1 inhibitors are advancing in both oncology and CNS.
Scrip - June 18, 2026
The Spanish biotech’s LSD1 inhibitors are advancing in both oncology and CNS.
Scrip - June 18, 2026
F2G, Shionogi Report Positive Phase III Results For Antifungal Olorofim In Invasive Aspergillosis
The companies have delivered positive late-stage data for investigational antifungal olorofim, marking a key development in the program's trajectory.
Scrip - June 18, 2026
The companies have delivered positive late-stage data for investigational antifungal olorofim, marking a key development in the program's trajectory.
Scrip - June 18, 2026
Biogen Buys RayThera, The Third Exit For Its Serial Founders
The founders of RayThera complete a hat-trick as Biogen snaps up the immunology-focused biotech for up to $1bn.
Scrip - June 18, 2026
The founders of RayThera complete a hat-trick as Biogen snaps up the immunology-focused biotech for up to $1bn.
Scrip - June 18, 2026
GLP-1s, Insulins Reshaping China’s Drug Exports, Thanks To MNCs
As multinationals switched to partly supplying global markets from manufacturing facilities in China, the country’s exports of GLP-1 and insulin analog preparations surged in 2025 and well into 2026.
Scrip - June 18, 2026
As multinationals switched to partly supplying global markets from manufacturing facilities in China, the country’s exports of GLP-1 and insulin analog preparations surged in 2025 and well into 2026.
Scrip - June 18, 2026
READI-Home FAQ: Modified Devices, Software And Pediatric Products All In Scope, FDA Confirms
A new FAQ for the FDA's READI-Home Innovation Challenge confirms that modified devices, software regulated as devices, and pediatric products may all be eligible for the program, which is designed to accelerate authorization of home-use devices that can help reduce hospital readmissions.
Medtech Insight - June 18, 2026
A new FAQ for the FDA's READI-Home Innovation Challenge confirms that modified devices, software regulated as devices, and pediatric products may all be eligible for the program, which is designed to accelerate authorization of home-use devices that can help reduce hospital readmissions.
Medtech Insight - June 18, 2026
Integrum Creates AI Bionics Unit Afyri As Ukraine Reimbursement Decision Looms
Swedish bone-anchored prosthetics firm Integrum created subsidiary Afyri, led by Integrum founder Rickard Brånemark, to drive a next-gen intelligent bionics platform. Integrum awaits a reimbursement decision for its OPRA implant in Ukraine, where it has been used in over 100 surgeries since 2023.
Medtech Insight - June 18, 2026
Swedish bone-anchored prosthetics firm Integrum created subsidiary Afyri, led by Integrum founder Rickard Brånemark, to drive a next-gen intelligent bionics platform. Integrum awaits a reimbursement decision for its OPRA implant in Ukraine, where it has been used in over 100 surgeries since 2023.
Medtech Insight - June 18, 2026
PwC Finds Once-Quiet Medtech Deal Market Getting Louder In 2026
A PwC outlook finds record deal value masked by historically thin transaction volumes — and flags portfolio reshaping, private equity and AI as the forces most likely to define 2026.
Medtech Insight - June 18, 2026
A PwC outlook finds record deal value masked by historically thin transaction volumes — and flags portfolio reshaping, private equity and AI as the forces most likely to define 2026.
Medtech Insight - June 18, 2026
Execs On The Move: June 8–12, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 18, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - June 18, 2026
Clue-SDK Deal Opens A Parallel Route For Femtech Into Insured Care, Bypassing Germany’s DiGA
German private insurer SDK is funding access to Clue's period-tracking app for its members, a move Clue calls a world first. The deal sidesteps Germany's DiGA reimbursement framework, hinting at a parallel route for femtech into insured benefits.
Medtech Insight - June 18, 2026
German private insurer SDK is funding access to Clue's period-tracking app for its members, a move Clue calls a world first. The deal sidesteps Germany's DiGA reimbursement framework, hinting at a parallel route for femtech into insured benefits.
Medtech Insight - June 18, 2026
EU Omnibus VI Provisional Agreement Advances CMR Phase-Out For Beauty
The provisional Omnibus VI agreement would introduce new transition periods for cosmetics containing newly classified CMR substances; the agreement is lauded by cosmetics and fragrance industry groups.
HBW Insight - June 18, 2026
The provisional Omnibus VI agreement would introduce new transition periods for cosmetics containing newly classified CMR substances; the agreement is lauded by cosmetics and fragrance industry groups.
HBW Insight - June 18, 2026
Solius Labs’ Wall-Mountable Light Launches As First FDA-Cleared OTC UVB Therapy Device
New FDA product code and $2,995 price, with no insurance required, position Solius Labs' personalized UVB panel as a scalable alternative to clinic-based phototherapy.
HBW Insight - June 18, 2026
New FDA product code and $2,995 price, with no insurance required, position Solius Labs' personalized UVB panel as a scalable alternative to clinic-based phototherapy.
HBW Insight - June 18, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry, marketplace news: FTC prioritizes false claims for children’s products; FDA maintains industry’s GMP annual burden; kidney injury warning added to alli label; more formula safety troubles; Texas investigates protein; Ohio hemp reg delayed.
HBW Insight - June 18, 2026
Weekly digest of US consumer health industry, marketplace news: FTC prioritizes false claims for children’s products; FDA maintains industry’s GMP annual burden; kidney injury warning added to alli label; more formula safety troubles; Texas investigates protein; Ohio hemp reg delayed.
HBW Insight - June 18, 2026
‘No Compromise’: How Opella Is Tackling The Hardest Parts Of Sustainability
Opella's chief manufacturing and supply officer, Rafik Amrane, talks to HBW Insight about the company's commitment to sustainability, emphasizing "there’s absolutely no compromise on what we do.”
HBW Insight - June 18, 2026
Opella's chief manufacturing and supply officer, Rafik Amrane, talks to HBW Insight about the company's commitment to sustainability, emphasizing "there’s absolutely no compromise on what we do.”
HBW Insight - June 18, 2026
US Supplement Industry Questions Sources For Texas AG’s ‘Harmful Ingredients’ Investigation
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
The Generics Bulletin Podcast: Probing The Patent Monopoly With I-MAK’s Tahir Amin
Generics Bulletin senior reporter Urt? Fultinavi?i?t? talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
Generics Bulletin - June 18, 2026
Generics Bulletin senior reporter Urt? Fultinavi?i?t? talks to Tahir Amin, co-founder and CEO of I-MAK, about the current intellectual property system that curtails off-patent drug competition and global health equity.
Generics Bulletin - June 18, 2026
Dr Reddy’s Challenges Bosulif With 180-Day Lead
Through a partnership with MSN Laboratories, Dr Reddy’s has launched the first US generic version of Bosulif (bosutinib) 400mg tablets with 180-day exclusivity.
Generics Bulletin - June 18, 2026
Through a partnership with MSN Laboratories, Dr Reddy’s has launched the first US generic version of Bosulif (bosutinib) 400mg tablets with 180-day exclusivity.
Generics Bulletin - June 18, 2026
Sumatriptan Surge Drives UK Price Rises In May
Generic sumatriptan 50mg and 100mg tablets saw their average UK trade prices increase by more than five times in May, leading a raft of triple-digit rises that also included multiple presentations of digoxin.
Generics Bulletin - June 18, 2026
Generic sumatriptan 50mg and 100mg tablets saw their average UK trade prices increase by more than five times in May, leading a raft of triple-digit rises that also included multiple presentations of digoxin.
Generics Bulletin - June 18, 2026
FDA Review Revives Outlook’s Long-Delayed Bevacizumab Hopes
Outlook Therapeutics is nearing a pivotal FDA decision on Lytenava, raising hopes that the US could soon get its first approved ophthalmic bevacizumab for wet AMD after years of regulatory setbacks.
Generics Bulletin - June 18, 2026
Outlook Therapeutics is nearing a pivotal FDA decision on Lytenava, raising hopes that the US could soon get its first approved ophthalmic bevacizumab for wet AMD after years of regulatory setbacks.
Generics Bulletin - June 18, 2026
Italian Strikes Cloud Teva’s TAPI Divestment Plans
Teva’s TAPI restructuring is drawing labor opposition in Italy as its Villanterio site faces potential closure, while around 250 roles are set to go in Israel, as the API unit remains marked for eventual divestment.
Generics Bulletin - June 18, 2026
Teva’s TAPI restructuring is drawing labor opposition in Italy as its Villanterio site faces potential closure, while around 250 roles are set to go in Israel, as the API unit remains marked for eventual divestment.
Generics Bulletin - June 18, 2026
Deals In Depth: May 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026